Current Diabetes Reports

, 8:60

Fatty liver, insulin resistance, and dyslipidemia

Article
  • 271 Downloads

Abstract

After recently being recognized as a feature of the metabolic syndrome, fatty liver has evolved as a key player in the pathogenesis of dyslipidemia. Development of nonalcoholic fatty liver disease comes from an imbalance between the influx and production of fatty acids and the use of fatty acids for oxidation or secretion as very low density lipoprotein (VLDL) triglycerides. Previously, we have shown a strong relationship between increased liver fat and overproduction of large VLDL particles. We observed recently that in patients with high liver fat, insulin was unable to regulate VLDL production. The result is increased concentrations of VLDL particles in the circulation. Consequently, changes are seen in the metabolism of other lipoproteins that interact with VLDL particles, the net result being decreased high-density lipoprotein cholesterol and increased formation of small, dense low-density lipoprotein. In this article, we review recent findings on the development of fatty liver and its role in the diabetic dyslipidemia pathogenesis.

References and Recommended Reading

  1. 1.
    Goldberg IJ, Ginsberg HN: Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology 2006, 130:1343–1346.PubMedCrossRefGoogle Scholar
  2. 2.
    Marchesini G, Bugianesi E, Forlani G, et al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917–923.PubMedCrossRefGoogle Scholar
  3. 3.
    Targher G, Bertolini L, Poli F, et al.: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54:3541–3546.PubMedCrossRefGoogle Scholar
  4. 4.
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183–1192.PubMedCrossRefGoogle Scholar
  5. 5.
    Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733–749.PubMedCrossRefGoogle Scholar
  6. 6.
    Ginsberg HN, Zhang YL, Hernandez-Ono A: Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 2006, 14(suppl 1):41S–49S.Google Scholar
  7. 7.
    Adiels M, Olofsson SO, Taskinen MR, Boren J: Diabetic dyslipidaemia. Curr Opin Lipidol 2006, 17:238–246.PubMedCrossRefGoogle Scholar
  8. 8.
    Westerbacka J, Lammi K, Hakkinen AM, et al.: Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005, 90:2804–2809.PubMedCrossRefGoogle Scholar
  9. 9.
    Kabir M, Catalano KJ, Ananthnarayan S, et al.: Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005, 288:E454–E461.PubMedCrossRefGoogle Scholar
  10. 10.
    Samuel VT, Liu ZX, Qu X, et al.: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345–32353.PubMedCrossRefGoogle Scholar
  11. 11.
    Boden G, She P, Mozzoli M, et al.: Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-{kappa}B pathway in rat liver. Diabetes 2005, 54:3458–3465.PubMedCrossRefGoogle Scholar
  12. 12.
    Hammond LE, Neschen S, Romanelli AJ, et al.: Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential in liver for the metabolism of excess acyl-CoAs. J Biol Chem 2005, 280:25629–25636.PubMedCrossRefGoogle Scholar
  13. 13.
    Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171–176.PubMedCrossRefGoogle Scholar
  14. 14.
    Choi CS, Savage DB, Kulkarni A, et al.: Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007, 282:22678–22688.PubMedCrossRefGoogle Scholar
  15. 15.
    Parks EJ, Hellerstein MK: Thematic review series: patientoriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. J Lipid Res 2006, 47:1651–1660.PubMedCrossRefGoogle Scholar
  16. 16.
    Barrows BR, Parks EJ: Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 2006, 91:1446–1452.PubMedCrossRefGoogle Scholar
  17. 17.
    Donnelly KL, Smith CI, Schwarzenberg SJ, et al.: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343–1351.PubMedCrossRefGoogle Scholar
  18. 18.
    Farquhar JW, Gross RC, Wagner RM, Reaven GM: Validation of an incompletely coupled two-compartment nonrecycling catenary model for turnover of liver and plasma triglyceride in man. J Lipid Res 1965, 6:119–134.PubMedGoogle Scholar
  19. 19.
    Parks EJ, Krauss RM, Christiansen MP, et al.: Effects of a lowfat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Invest 1999, 104:1087–1096.PubMedGoogle Scholar
  20. 20.
    Havel RJ: Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metabolism 1961, 10:1031–1034.PubMedGoogle Scholar
  21. 21.
    Tamura S, Shimomura I: Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1139–1142.PubMedCrossRefGoogle Scholar
  22. 22.
    Adiels M, Westerbacka J, Soro-Paavonen A, et al.: Acute suppression of VLDL(1) secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007, 50:2356–2365.PubMedCrossRefGoogle Scholar
  23. 23.
    Adiels M, Taskinen MR, Packard C, et al.: Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755–765.PubMedCrossRefGoogle Scholar
  24. 24.
    Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147–152.PubMedCrossRefGoogle Scholar
  25. 25.
    Shimomura I, Bashmakov Y, Horton JD: Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999, 274:30028–30032.PubMedCrossRefGoogle Scholar
  26. 26.
    Koo SH, Dutcher AK, Towle HC: Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J Biol Chem 2001, 276:9437–9445.PubMedCrossRefGoogle Scholar
  27. 27.
    Musso G, Gambino R, De Michieli F, et al.: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909–916.PubMedCrossRefGoogle Scholar
  28. 28.
    Vedala A, Wang W, Neese RA, et al.: Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. J Lipid Res 2006, 47:2562–2574.PubMedCrossRefGoogle Scholar
  29. 29.
    Adiels M, Packard C, Caslake MJ, et al.: A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 2005, 46:58–67.PubMedCrossRefGoogle Scholar
  30. 30.
    Adiels M, Boren J, Caslake MJ, et al.: Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005, 25:1697–1703.PubMedCrossRefGoogle Scholar
  31. 31.
    Prinsen BH, Romijn JA, Bisschop PH, et al.: Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. J Lipid Res 2003, 44:1341–1348.PubMedCrossRefGoogle Scholar
  32. 32.
    Gill JM, Brown JC, Bedford D, et al.: Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 2004, 176:49–56.PubMedCrossRefGoogle Scholar
  33. 33.
    Riches FM, Watts GF, Naoumova RP, et al.: Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998, 22:414–423.PubMedCrossRefGoogle Scholar
  34. 34.
    Chan DC, Watts GF, Redgrave TG, et al.: Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002, 51:1041–1046.PubMedCrossRefGoogle Scholar
  35. 35.
    Watts GF, Barrett PH, Ji J, et al.: Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803–811.PubMedCrossRefGoogle Scholar
  36. 36.
    Verges B: New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005, 31:429–439.PubMedCrossRefGoogle Scholar
  37. 37.
    Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495–506.PubMedGoogle Scholar
  38. 38.
    Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69–75.PubMedGoogle Scholar
  39. 39.
    Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 1996, 276:875–881.CrossRefGoogle Scholar
  40. 40.
    Rashid S, Watanabe T, Sakaue T, Lewis GF: Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421–429.PubMedCrossRefGoogle Scholar
  41. 41.
    Chan DC, Barrett PH, Watts GF: Lipoprotein transport in the metabolic syndrome (Part I): methodological aspects of stable isotope kinetic studies. Clin Sci (Lond) 2004, 107:221–232.CrossRefGoogle Scholar
  42. 42.
    Chan DC, Barrett PH, Watts GF: Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 2006, 17:28–36.PubMedCrossRefGoogle Scholar
  43. 43.
    Marsh JB, Welty FK, Lichtenstein AH, et al.: Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002, 162:227–244.PubMedCrossRefGoogle Scholar
  44. 44.
    Zech LA, Grundy SM, Steinberg D, Berman M: Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects. J Clin Invest 1979, 63:1262–1273.PubMedGoogle Scholar
  45. 45.
    Magkos F, Sidossis LS: Measuring very low density lipoprotein-triglyceride kinetics in man in vivo: how different the various methods really are. Curr Opin Clin Nutr Metab Care 2004, 7:547–555.PubMedCrossRefGoogle Scholar
  46. 46.
    Lewis GF, Uffelman KD, Szeto LW, Steiner G: Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993, 42:833–842.PubMedCrossRefGoogle Scholar
  47. 47.
    Malmstrom R, Packard CJ, Caslake M, et al.: Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998, 47:779–787.PubMedCrossRefGoogle Scholar
  48. 48.
    Linden D, Alsterholm M, Wennbo H, Oscarsson J: PPARalpha deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins. J Lipid Res 2001, 42:1831–1840.PubMedGoogle Scholar
  49. 49.
    Linden D, Lindberg K, Oscarsson J, et al.: Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. J Biol Chem 2002, 277:23044–23053.PubMedCrossRefGoogle Scholar
  50. 50.
    Ameen C, Edvardsson U, Ljungberg A, et al.: Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem 2005, 280:1224–1229.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Martin Adiels
    • 1
  • Marja-Riitta Taskinen
  • Jan Borén
  1. 1.WallenberglaboratorietSahlgrenska University HospitalGöteborgSweden

Personalised recommendations